Lantheus Holdings, Inc. sold $246K of CATX
Lantheus Holdings, Inc. sold 78,145 shares of Perspective Therapeutics, Inc. (CATX) at $3.14 ($0.25M total) on 2026-08-31.
How this was made
The 30-second read
Why it matters
The disclosed sale represents a modest reduction in a large insider position, unlikely to move the stock materially.
Market read
Primary disclosure of a small insider sale; low trading relevance.
What to watch
The sale could be a routine liquidity event unrelated to company fundamentals.
Background
Perspective Therapeutics (NASDAQ: CATX) is a clinical‑stage biotech. Lantheus Holdings reported a direct sale of shares under a Form 4 filing.
Ticker impact
SEC Form 4 shows Lantheus sold 78,145 Perspective Therapeutics shares for $245.6K on 2026-08-31.
Limited short‑term impact; price likely unchanged.
The transaction is small relative to total float and does not constitute a material change in ownership.
Market effects
Minimal; insider activity does not affect broader biotech sector.
None; transaction is US‑listed but small.
None
Counterpoint
Some traders may view any insider sell as a bearish signal and short the stock.
Key entities
- companyPerspective Therapeutics, Inc.
Biotech issuer of the shares sold.
- insiderLantheus Holdings, Inc.
Reporter of the Form 4 and 10% owner.